Retatrutide Weight Loss Research: What Phase 2 and Phase 3 Trials Actually Show
TLDR Retatrutide has produced some of the largest average weight reductions reported in randomized obesity-drug trials, but the evidence needs to be read carefully. The strongest peer-reviewed obesity result remains the 2023 Phase 2 trial: participants receiving 12 mg lost an average 24.2% of baseline body weight at 48 weeks. Higher doses produced greater weight … Read more